Cerulean Pharma Inc. (CERU) 5.99 $CERU
Cerulean Announces Three Posters to be Presented with Preclinical CRLX101 Data at the American Association for Cancer Research Annual Meeting
Business Wire - Thu Apr 16, 6:02AM CDT
--CRLX101 monotherapy and in combination with Avastin shrinks tumors and prevents new metastases
CERU: 5.99 (-0.20)
Cerulean Announces Publication Showing CRLX101 Targets Breast Cancer Stem Cells and Impedes Resistance to Anti-angiogenic Therapy in Preclinical Models
Business Wire - Mon Apr 13, 6:22AM CDT
Cerulean Pharma Inc. (Nasdaq:CERU), a leader in Dynamic Tumor Targeting(TM), today announced the publication of a manuscript in Breast Cancer Research and Treatment, describing preclinical data that demonstrate CRLX101, Cerulean's lead proprietary investigational drug, targets breast cancer stem cells and impedes resistance to anti-angiogenic therapy in breast cancer mouse models.
CERU: 5.99 (-0.20)
Cerulean concludes public offering of 6.716m common stock
M2 - Mon Apr 13, 5:34AM CDT
Cancer treatment company Cerulean Pharma (Nasdaq:CERU) said on Friday that it has completed its public offering of 6,716,000 shares of common stock at a public offering price of USD6.00 per share.
CERU: 5.99 (-0.20)
InsiderInsights.com Daily Round Up 4/9/15: OVAS, AGCO, OPK, OGES
InsiderInsights - at Seeking Alpha - Fri Apr 10, 8:58AM CDT
ASH: 127.06 (+0.15), STFC: 23.83 (-0.01), MNST: 139.91 (+0.06), OVAS: 29.85 (-0.24), CERU: 5.99 (-0.20), AGCO: 48.16 (-0.16), GIII: 116.32 (-1.15), ASTI: 1.07 (+0.04), PANW: 153.87 (-0.50), TNET: 35.45 (-0.54), DRI: 65.20 (-0.09), FMI: 48.71 (-0.96), LNKD: 259.35 (+0.93), OPK: 14.60 (+0.17), DWRE: 65.40 (+1.36), RAVN: 20.69 (-0.04), TWTR: 51.73 (+0.41)
Cerulean Closes Public Offering of Common Stock
Business Wire - Fri Apr 10, 8:31AM CDT
Cerulean Pharma Inc. (Nasdaq: CERU) today announced the closing of its underwritten public offering of 6,716,000 shares of common stock, including 876,000 shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares, at a public offering price of $6.00 per share. The gross proceeds to Cerulean from this offering were approximately $40.3 million, before deducting underwriting discounts and commissions and offering expenses payable by Cerulean.
CERU: 5.99 (-0.20)
Cerulean to Present at 14th Annual Needham Healthcare Conference
Business Wire - Wed Apr 08, 6:02AM CDT
Cerulean Pharma Inc. (Nasdaq: CERU), a leader in Dynamic Tumor Targeting(TM), today announced that Christopher D. T. Guiffre, President and Chief Executive Officer, will present at the 14th Annual Needham Healthcare Conference on Wednesday, April 15th at 5:00 p.m. ET in New York.
CERU: 5.99 (-0.20)
Nasdaq stocks posting largest volume increases
AP - Tue Apr 07, 5:15PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
JASN: 7.48 (-0.14), INFA: 47.92 (-0.03), TFSC: 9.70 (+0.09), QURE: 26.15 (-1.44), CERU: 5.99 (-0.20), SYRX: 2.09 (-0.05), NECB: 7.78 (-0.02), ESMC: 1.36 (-0.01), VLTC: 15.14 (-1.04), CBMG: 32.14 (+2.21), HCBK: 9.45 (+0.08), OCUL: 25.90 (-0.05)
Nasdaq stocks posting largest percentage decreases
AP - Tue Apr 07, 5:15PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
VBFC: 19.86 (-0.12), IIIN: 21.41 (+0.20), CERU: 5.99 (-0.20), RCPT: 166.76 (-3.37), MGPI: 14.45 (+0.16), SCC.TO: 9.51 (-0.43), CBMG: 32.14 (+2.21), HCBK: 9.45 (+0.08), DGLY: 13.13 (+0.08), SRSC: 7.81 (-0.15), OCUL: 25.90 (-0.05), IKNX: 14.75 (-0.11)
Cerulean prices public offering at USD6.00 per share
M2 - Tue Apr 07, 6:57AM CDT
Cancer treatment company Cerulean Pharma (Nasdaq:CERU) said on Tuesday that it has priced a public offering of 5,840,000 shares of its common stock.
CERU: 5.99 (-0.20)
Cerulean prices equity offering
Seeking Alpha - at Seeking Alpha - Tue Apr 07, 5:58AM CDT
CERU: 5.99 (-0.20)
Cerulean Announces Pricing of Public Offering of Common Stock
Business Wire - Tue Apr 07, 5:03AM CDT
Cerulean Pharma Inc. (Nasdaq: CERU) today announced the pricing of an underwritten public offering of 5,840,000 shares of its common stock at a public offering price of $6.00 per share, before underwriting discounts. All of the shares in the offering are being offered by Cerulean. In addition, Cerulean has granted the underwriters an option for a period of 30 days to purchase up to 876,000 additional shares of common stock at the public offering price, less underwriting discounts.
CERU: 5.99 (-0.20)
Cerulean: Recently Announced Secondary Provides Interesting Opportunity
Chris Bunge - at Seeking Alpha - Mon Apr 06, 8:38PM CDT
CERU: 5.99 (-0.20)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Thu Apr 02, 8:13AM CDT
KMX: 70.84 (-0.04), CARB: 11.14 (-0.07), TXMD: 7.17 (+0.01), CERU: 5.99 (-0.20), CNAT: 6.31 (-0.15), RPRX: 8.36 (-0.15), LBIO: 12.50 (+0.50), FXCM: 2.13 (+0.02), CAPN: 6.99 (-0.29), WBAI: 16.75 (-0.46)
Cerulean initiates equity offering
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 3:32PM CDT
CERU: 5.99 (-0.20)
Cerulean Announces Proposed Public Offering of Common Stock
Business Wire - Mon Mar 30, 3:20PM CDT
Cerulean Pharma Inc. (Nasdaq: CERU) today announced that it has commenced an underwritten public offering of approximately $50 million of shares of its common stock. The number of shares to be offered and the price per share for the proposed offering have not yet been determined. All of the shares in the offering are to be sold by Cerulean.
CERU: 5.99 (-0.20)
Cerulean Pharma (CERU) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 23, 6:42AM CDT
Cerulean Pharma (CERU) Shares March Higher, Can It Continue?
CERU: 5.99 (-0.20)
New chief at Cerulean Pharma
Seeking Alpha - at Seeking Alpha - Sat Mar 21, 11:30AM CDT
CERU: 5.99 (-0.20)
Cerulean Appoints Chris Guiffre President & Chief Executive Officer
Business Wire - Fri Mar 20, 3:41PM CDT
Cerulean Pharma Inc. (Nasdaq: CERU), a leader in Dynamic Tumor Targeting(TM), today announced that Christopher D. T. Guiffre, J.D., M.B.A., has been appointed President & Chief Executive Officer.
CERU: 5.99 (-0.20)
Cerulean Announces Three Posters to be Presented with Preclinical CRLX101 Data at the American Association for Cancer Research Annual Meeting
Business Wire - Thu Apr 16, 6:02AM CDT
--CRLX101 monotherapy and in combination with Avastin shrinks tumors and prevents new metastases
CERU: 5.99 (-0.20)
Cerulean Announces Publication Showing CRLX101 Targets Breast Cancer Stem Cells and Impedes Resistance to Anti-angiogenic Therapy in Preclinical Models
Business Wire - Mon Apr 13, 6:22AM CDT
Cerulean Pharma Inc. (Nasdaq:CERU), a leader in Dynamic Tumor Targeting(TM), today announced the publication of a manuscript in Breast Cancer Research and Treatment, describing preclinical data that demonstrate CRLX101, Cerulean's lead proprietary investigational drug, targets breast cancer stem cells and impedes resistance to anti-angiogenic therapy in breast cancer mouse models.
CERU: 5.99 (-0.20)
Cerulean concludes public offering of 6.716m common stock
M2 - Mon Apr 13, 5:34AM CDT
Cancer treatment company Cerulean Pharma (Nasdaq:CERU) said on Friday that it has completed its public offering of 6,716,000 shares of common stock at a public offering price of USD6.00 per share.
CERU: 5.99 (-0.20)
InsiderInsights.com Daily Round Up 4/9/15: OVAS, AGCO, OPK, OGES
InsiderInsights - at Seeking Alpha - Fri Apr 10, 8:58AM CDT
ASH: 127.06 (+0.15), STFC: 23.83 (-0.01), MNST: 139.91 (+0.06), OVAS: 29.85 (-0.24), CERU: 5.99 (-0.20), AGCO: 48.16 (-0.16), GIII: 116.32 (-1.15), ASTI: 1.07 (+0.04), PANW: 153.87 (-0.50), TNET: 35.45 (-0.54), DRI: 65.20 (-0.09), FMI: 48.71 (-0.96), LNKD: 259.35 (+0.93), OPK: 14.60 (+0.17), DWRE: 65.40 (+1.36), RAVN: 20.69 (-0.04), TWTR: 51.73 (+0.41)
Cerulean Closes Public Offering of Common Stock
Business Wire - Fri Apr 10, 8:31AM CDT
Cerulean Pharma Inc. (Nasdaq: CERU) today announced the closing of its underwritten public offering of 6,716,000 shares of common stock, including 876,000 shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares, at a public offering price of $6.00 per share. The gross proceeds to Cerulean from this offering were approximately $40.3 million, before deducting underwriting discounts and commissions and offering expenses payable by Cerulean.
CERU: 5.99 (-0.20)
Cerulean to Present at 14th Annual Needham Healthcare Conference
Business Wire - Wed Apr 08, 6:02AM CDT
Cerulean Pharma Inc. (Nasdaq: CERU), a leader in Dynamic Tumor Targeting(TM), today announced that Christopher D. T. Guiffre, President and Chief Executive Officer, will present at the 14th Annual Needham Healthcare Conference on Wednesday, April 15th at 5:00 p.m. ET in New York.
CERU: 5.99 (-0.20)
Nasdaq stocks posting largest volume increases
AP - Tue Apr 07, 5:15PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
JASN: 7.48 (-0.14), INFA: 47.92 (-0.03), TFSC: 9.70 (+0.09), QURE: 26.15 (-1.44), CERU: 5.99 (-0.20), SYRX: 2.09 (-0.05), NECB: 7.78 (-0.02), ESMC: 1.36 (-0.01), VLTC: 15.14 (-1.04), CBMG: 32.14 (+2.21), HCBK: 9.45 (+0.08), OCUL: 25.90 (-0.05)
Nasdaq stocks posting largest percentage decreases
AP - Tue Apr 07, 5:15PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
VBFC: 19.86 (-0.12), IIIN: 21.41 (+0.20), CERU: 5.99 (-0.20), RCPT: 166.76 (-3.37), MGPI: 14.45 (+0.16), SCC.TO: 9.51 (-0.43), CBMG: 32.14 (+2.21), HCBK: 9.45 (+0.08), DGLY: 13.13 (+0.08), SRSC: 7.81 (-0.15), OCUL: 25.90 (-0.05), IKNX: 14.75 (-0.11)
Cerulean prices public offering at USD6.00 per share
M2 - Tue Apr 07, 6:57AM CDT
Cancer treatment company Cerulean Pharma (Nasdaq:CERU) said on Tuesday that it has priced a public offering of 5,840,000 shares of its common stock.
CERU: 5.99 (-0.20)
Cerulean prices equity offering
Seeking Alpha - at Seeking Alpha - Tue Apr 07, 5:58AM CDT
CERU: 5.99 (-0.20)
Cerulean Announces Pricing of Public Offering of Common Stock
Business Wire - Tue Apr 07, 5:03AM CDT
Cerulean Pharma Inc. (Nasdaq: CERU) today announced the pricing of an underwritten public offering of 5,840,000 shares of its common stock at a public offering price of $6.00 per share, before underwriting discounts. All of the shares in the offering are being offered by Cerulean. In addition, Cerulean has granted the underwriters an option for a period of 30 days to purchase up to 876,000 additional shares of common stock at the public offering price, less underwriting discounts.
CERU: 5.99 (-0.20)
Cerulean: Recently Announced Secondary Provides Interesting Opportunity
Chris Bunge - at Seeking Alpha - Mon Apr 06, 8:38PM CDT
CERU: 5.99 (-0.20)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Thu Apr 02, 8:13AM CDT
KMX: 70.84 (-0.04), CARB: 11.14 (-0.07), TXMD: 7.17 (+0.01), CERU: 5.99 (-0.20), CNAT: 6.31 (-0.15), RPRX: 8.36 (-0.15), LBIO: 12.50 (+0.50), FXCM: 2.13 (+0.02), CAPN: 6.99 (-0.29), WBAI: 16.75 (-0.46)
Cerulean initiates equity offering
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 3:32PM CDT
CERU: 5.99 (-0.20)
Cerulean Announces Proposed Public Offering of Common Stock
Business Wire - Mon Mar 30, 3:20PM CDT
Cerulean Pharma Inc. (Nasdaq: CERU) today announced that it has commenced an underwritten public offering of approximately $50 million of shares of its common stock. The number of shares to be offered and the price per share for the proposed offering have not yet been determined. All of the shares in the offering are to be sold by Cerulean.
CERU: 5.99 (-0.20)
Cerulean Pharma (CERU) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 23, 6:42AM CDT
Cerulean Pharma (CERU) Shares March Higher, Can It Continue?
CERU: 5.99 (-0.20)
New chief at Cerulean Pharma
Seeking Alpha - at Seeking Alpha - Sat Mar 21, 11:30AM CDT
CERU: 5.99 (-0.20)
Cerulean Appoints Chris Guiffre President & Chief Executive Officer
Business Wire - Fri Mar 20, 3:41PM CDT
Cerulean Pharma Inc. (Nasdaq: CERU), a leader in Dynamic Tumor Targeting(TM), today announced that Christopher D. T. Guiffre, J.D., M.B.A., has been appointed President & Chief Executive Officer.
CERU: 5.99 (-0.20)
